Current evidence reveals prominent PI3K/AKT signaling in NRAS G12 mutant cells and augmented MAPK signaling in NRAS Q61 variants, suggesting that NRAS G12 and NRAS Q61-mutant melanoma tumors differ in biology. The gene discussed is NRAS; the disease is melanoma.